Cover Image
市場調查報告書

腸泌素(Incretin)藥物:糖尿病療法市場與治療法開發

Incretin-Based Drugs: Markets for Diabetes Therapies and Developing Treatments

出版商 BCC Research 商品編碼 324910
出版日期 內容資訊 英文 136 Pages
訂單完成後即時交付
價格
Back to Top
腸泌素(Incretin)藥物:糖尿病療法市場與治療法開發 Incretin-Based Drugs: Markets for Diabetes Therapies and Developing Treatments
出版日期: 2015年02月25日 內容資訊: 英文 136 Pages
簡介

全球腸泌素藥物市場以2013年約118億美金、2014年約127億美金的規模寫下紀錄。預估從2014年到2019年可以12.4%的CAGR成長,在2019年可望達成228億美金規模。

本報告針對治療糖尿病之腸泌素藥物市場進行調查,彙整了糖尿病及糖尿病治療的概要、已上市之腸泌素藥物及開發中的候補化合物種類與概意、開發中藥物的動向、腸泌素藥物的市場規模變度與預測、各種影響市場成長的因素分析、主要企業檔案等內容,以摘要形式提供如後。

第1章 前言

第2章 報告摘要

  • 藉由腸泌素控制血糖
  • 配藥與販賣趨勢

第3章 概要、市場預測

  • 糖尿病標準治療
    • METFORMIN
    • 硫□基尿素類(SU)
    • 塞唑烷二酮類(TZD)
    • α葡萄糖甘□抑制劑
    • 胰島素療法
      • 長效型胰島素
      • 中效型胰島素
      • 普通、短效型胰島素
      • 速效型胰島素
    • 其他新療法
  • 糖尿病詳細解說
    • 糖尿病的種類
      • 第1型糖尿病
      • 第2型糖尿病
      • 妊娠糖尿病
      • 葡萄糖耐受不良(IGT)、空腹血糖偏高(IFG)
    • 腸泌素的照護模型
    • 糖尿病相關症狀
      • 肥胖
      • 心血管疾病
      • 胰臟炎
      • 癌症
      • 多囊性卵巢症候群
    • 併發症、共病症
  • 使用腸泌素的治療
  • GLP-1受體拮抗劑
  • 已上市GLP-1受體拮抗劑
    • Exenatide
    • Liraglutide
    • Dulaglutide
    • Albiglutide
    • Lixisenatide
  • 已上市DPP-4抑制劑
    • Linagliptin
    • Sitagliptin
    • Vildagliptin
    • Saxagliptin
    • Alogliptin
    • Teneligliptin
    • Anagliptin
    • Gemigliptin
  • 市場環境
  • 腸泌素市場交易

第4章 開發中候補藥物

  • 法規環境
  • 專利
  • 開發中候補藥物
  • 開發中的主要GLP-1受體拮抗劑
  • 開發中的主要DPP-4抑制劑
  • 開發案個案研究:PHENOMIX
  • 有前途的候補藥物與新研究
    • 進展中的新候補藥物
      • GLP-1/昇糖素雙重拮抗劑
      • 昇糖素受體拮抗劑
      • GLP-2
      • GPR119
      • TGR5
      • 葡萄糖激□活化劑
    • 其他新研究
      • Imperial College London
      • Orgenesis
    • 研發環境:整體藥物市場
    • 糖尿病的銷售區域
    • 生物製劑與GLP-1受體拮抗劑的生產
      • 成長因素
      • 基因治療
      • 基因重組蛋白質
      • 單株抗體
  • 生物製劑的環境
  • 糖尿病、糖尿病相關藥物的開發線
  • 肥胖已成治療項目

第5章 企業檔案

  • ACTIVX BIOSCIENCES INC.
  • AERPIO THERAPEUTICS INC.
  • AMPIO PHARMACEUTICALS INC.
  • AMUNIX
  • ARAIM PHARMACEUTICALS INC.
  • ARISAPH
  • ASTRAZENECA
  • BECTON, DICKINSON AND COMPANY
  • BOEHRINGER INGELHEIM GMBH
  • BRISTOL-MYERS SQUIBB
  • CEBIX INC.
  • CHEMOCENTRYX INC.
  • CODA THERAPEUTICS INC.
  • CONCERT PHARMACEUTICALS
  • CONJUCHEM
  • DIPEXIUM PHARMACEUTICALS INC.
  • DONG-A SOCIO HOLDINGS
  • ELI LILLY AND COMPANY
  • EMISPHERE TECHNOLOGIES INC.
  • EVOKE PHARMA INC.
  • FURIEX PHARMACEUTICALS INC.
  • GENKYOTEX S.A.
  • GLAXOSMITHKLINE PLC
  • GLYCADIA PHARMACEUTICALS
  • HANMI PHARMACEUTICAL CO. LTD.
  • ICO THERAPEUTICS INC.
  • INTARCIA THERAPEUTICS INC.
  • JOHNSON & JOHNSON
  • KOWA CO. LTD.
  • KYORIN PHARMACEUTICAL CO. LTD.
  • KYOWA HAKKO KIRIN CO. LTD.
  • LIGAND PHARMACEUTICALS INC.
  • LG LIFE SCIENCES LTD.
  • MANNKIND CORP.
  • MERCK
  • MERRION PHARMACEUTICALS LTD.
  • MITSUBISHI TANABE PHARMA CORP.
  • NEPHROGENEX INC.
  • NOVARTIS INTERNATIONAL AG
  • NOVO NORDISK A/S
  • ONO PHARMACEUTICALS
  • ORAMED PHARMACEUTICALS
  • OTSUKA PHARMACEUTICAL CO. LTD.
  • PFIZER
  • PHASEBIO PHARMACEUTICALS INC.
  • QUARK PHARMACEUTICALS INC.
  • ROCHE
  • ROYER BIOMEDICAL INC.
  • SANOFI
  • SANWA KAGAKU KENKYUSHO CO. LTD.
  • SATRX LLC
  • SIHUAN PHARMACEUTICAL HOLDINGS GROUP CO. LTD.
  • TAKEDA PHARMACEUTICAL CO. LTD.
  • TRANSITION THERAPEUTICS INC.
  • TRANSTECH PHARMA LLC
  • VIKING THERAPEUTICS INC.
  • ZEALAND PHARMA A/S
  • ZOSANO PHARMA CORP.

圖表清單

目錄
Product Code: PHM162A

REPORT HIGHLIGHTS

The global market for incretin-based therapeutics was valued at nearly $11.8 billion in 2013 and $12.7 billion in 2014. This market is expected to reach $22.8 billion by 2019, with a compound annual growth rate (CAGR) of 12.4% from 2014 to 2019.

This report provides:

  • An overview of the global diabetes treatment market.
  • Analyses of global market trends, with data from 2012 to 2014, and projections of CAGRs through 2019.
  • Information on the field of glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors collectively known as incretin-based therapies, a drug category used mainly for the control of diabetes but that also have potential indications for cardiovascular treatment and even weight loss.
  • Drug sales earned according to therapeutic area as well as by geography.
  • Analysis of the market's dynamics, specifically major issues, and challenges.
  • Relevant intellectual property (IP) and patent analysis.

SCOPE OF REPORT

The scope of this study encompasses companies that are involved in diabetes prevention as well as detection, diagnosis and treatment. BCC Research analyzes each technology or therapy type, determines its current market status, examines its impact on future markets and presents forecasts of growth over the next five years. Technological issues, including the latest trends, are discussed.

ANALYST'S CREDENTIALS

Kim Lawson is a graduate of Mount Holyoke College with a degree in English Literature and a M.A in management from Harvard University's extension program. She acquired experience as a healthcare journalist, including working for John Wiley & Sons as a print reporter, before serving as a research analyst in a small market research firm in the Research Triangle Park area of North Carolina and which focused on pharmaceuticals and biotechnology. Before joining that firm, Lawson published two reports on emerging and established diagnostics and therapeutics for benign and cancerous breast disease.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THIS STUDY
  • SCOPE OF REPORT
  • INTENDED AUDIENCE
  • METHODOLOGY
  • INFORMATION SOURCES
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 - EXECUTIVE SUMMARY

  • INCRETINS FILL NEED FOR GLYCEMIC CONTROL
  • TRENDS IN DISPENSING AND SALES
  • SUMMARY TABLE: GLOBAL MARKET FOR INCRETIN-BASED THERAPEUTICS, THROUGH 2019 ($ MILLIONS)
  • SUMMARY FIGURE: GLOBAL MARKET FOR INCRETIN-BASED THERAPEUTICS, 2012-2019 ($ MILLIONS)
    • GEOGRAPHICAL SHIFTS
    • KEY DRIVERS
    • KEY CHALLENGES
    • KEY TRENDS

CHAPTER 3 - OVERVIEW AND MARKET FORECAST

  • FIGURE 1: THE INCRETIN EFFECT ILLUSTRATED
  • FIGURE 2: PERCENTAGE OF DISPENSED PRESCRIPTIONS FOR NON-INSULIN ANTIDIABETICS, 2012 (%)
    • DATA ON WHERE INCRETINS FIT
      • FIGURE 3: PERCENTAGE OF DISPENSED PRESCRIPTIONS FOR GLP-1 RECEPTOR AGONISTS, 2012 (%)
      • FIGURE 4: PERCENTAGE OF DISPENSED PRESCRIPTIONS FOR DPP-4 INHIBITORS, 2012 (%)
    • FOR SOME, A GLP-1 FOCUS
      • TABLE 1: DIFFERENCES BETWEEN THE INCRETIN THERAPIES
  • STANDARD DIABETIC TREATMENTS
    • METFORMIN
    • SULFONYLUREAS (SU)
    • THIAZOLIDINEDIONE (TZD)
    • ALPHA-GLUCOSIDASE INHIBITORS
    • INSULIN TREATMENT
      • Long-acting Insulin
      • Intermediate-acting Insulin
      • Regular or Short-acting Insulin
      • Rapid-acting Insulin
        • TABLE 2: ADVANTAGES TO ADDING INCRETIN THERAPY
    • OTHER NEW TREATMENTS
  • DIABETES FURTHER EXPLAINED
    • TYPES OF DIABETES
      • Type 1
      • Type 2
      • Gestational Diabetes
      • Impaired Glucose Tolerance (IGT) and Impaired Fasting Glycemia (IFG)
    • CARE MODEL UPDATED WITH INCRETINS
    • CONDITIONS RELATED TO DIABETES
      • Obesity
        • FIGURE 5: ADA'S STANDARD OF MEDICAL CARE IN DIABETES, 2014
      • Cardiovascular Disease
      • Pancreatitis
      • Cancer
        • TABLE 3: CURRENT THINKING ON DIABETES MEDICATIONS AND CANCER RISK
      • Polycystic Ovary Syndrome
    • COMPLICATIONS AND COMORBIDITIES
      • TABLE 4: COMPLICATIONS/COMORBID CONDITIONS FROM DIABETES
  • INCRETIN THERAPIES
    • TABLE 5: COMMERCIALIZED INCRETIN THERAPY
  • GLP-1 RECEPTOR AGONISTS
  • COMMERCIALIZED GLP-1 RECEPTOR AGONISTS
    • Exenatide
    • Liraglutide
    • Dulaglutide
    • Albiglutide
    • Lixisenatide
  • COMMERCIALIZED DPP-4 INHIBITORS
    • Linagliptin
    • Sitagliptin
    • Vildagliptin
    • Saxagliptin
    • Alogliptin
    • Teneligliptin
    • Anagliptin
    • Gemigliptin
  • MARKET LANDSCAPE
    • TABLE 6: NUMBER OF COMMERCIALIZED INCRETIN-BASED THERAPEUTICS, 2014 AND 2019 (UNITS)
    • FIGURE 6: NUMBER OF COMMERCIALIZED INCRETIN-BASED THERAPEUTICS, 2014 AND 2019 (UNITS)
    • FIGURE 7: MARKET SHARE OF INCRETIN-BASED THERAPEUTICS, BY THERAPEUTIC AREA, 2014 AND 2019 (% OF REVENUE BY THERAPEUTIC AREA)
    • FIGURE 8: MARKET SHARE OF COMMERCIALIZED INCRETIN-BASED THERAPEUTICS, BY INCRETIN TYPE, 2014 AND 2019 (% OF REVENUE BY INCRETIN TYPE)
    • FIGURE 9: MARKET SHARE OF COMMERCIALIZED GLP-1 RECEPTOR AGONISTS, BY DOSING FREQUENCY, 2014 AND 2019 (%)
  • DEALS IN THE INCRETIN MARKET
    • TABLE 7: MAJOR AGREEMENTS FOR INCRETIN-BASED THERAPY DEVELOPMENT

CHAPTER 4 - THE DEVELOPMENT PIPELINE

  • REGULATORY ENVIRONMENT
  • PATENTS
  • DEVELOPMENT PIPELINE
    • FIGURE 10: NUMBER OF INCRETINS IN DEVELOPMENT BY PHASE, 2014
  • KEY GLP-1 RECEPTOR AGONISTS IN DEVELOPMENT
    • Exenatide Formulations (Including ICTA,
    • VRS-859/Exenatide-extended Release, and Microsphere Formulation of Exenatide, DA-3091)
    • Liraglutide for Obesity (Sandexa) and for Type 1 Diabetes (NN9211)
    • Lixisenatide (Lyxumia and LixiLan [Combined Lixisenatide and Basal Insulin])
    • Semaglutide (NN9535)
    • CJC-1134-PC
      • TABLE 8: GLP-1 RECEPTOR AGONISTS IN LATE-STAGE DEVELOPMENT
      • TABLE 9: GLP-1 RECEPTOR AGONISTS IN EARLY-STAGE DEVELOPMENT
  • KEY DPP-4 INHIBITORS IN DEVELOPMENT
    • Saxagliptin (Onglyza/)Dapagliflozin Combination (Forxiga)
    • Trelagliptin
    • Omarigliptin
    • Gosogliptin (Satyor)
    • Gemigliptin
      • TABLE 10: DPP-4 INHIBITORS IN LATE-STAGE DEVELOPMENT
      • TABLE 11: DPP-4 INHIBITORS IN EARLY-STAGE DEVELOPMENT
  • DEVELOPMENT CASE STUDY: PHENOMIX
  • PROMISING PIPELINE CANDIDATES AND NOVEL RESEARCH
    • NOVEL ACTIVE DRUG CANDIDATES
      • Dual GLP-1/Glucagon Agonists
      • Glucagon Receptor Agonists
      • GLP-2
      • GPR119
      • TGR5
      • Glucokinase Activators
    • OTHER NOVEL RESEARCH
      • Department of Medicine, Imperial College London, U.K.
      • Orgenesis' Conversion of Liver Cells
    • DEVELOPMENT LANDSCAPE: OVERALL PHARMA MARKET
      • TABLE 12: TOP PHARMA COMPANIES BY REVENUE, 2013 ($ BILLIONS)
      • FIGURE 11: GEOGRAPHIC DISTRIBUTION OF PHARMACEUTICAL DRUGS, 2012 AND 2017 (PERCENT OF GLOBAL SALES)
    • DIABETES AS SALES TERRITORY
      • FIGURE 12: DIABETES-FOCUSED GEOGRAPHIC TERRITORY: NOVO NORDISK SALES, 2013 (% OF SALES)
    • BIOLOGICS AND GLP-1 RECEPTOR AGONIST PRODUCTION
      • Growth Factors
      • Gene Therapy
      • Recombinant Proteins
      • Monoclonal Antibodies
  • BIOLOGIC LANDSCAPE
    • TABLE 13: BIOLOGICS IN DEVELOPMENT IN THE U.S. BY THERAPEUTIC CATEGORY, 2013
  • PIPELINE FOR DIABETES AND DIABETES-RELATED MEDICATIONS
    • TABLE 14: GLOBAL PIPELINE FOR PHASE II AND III STAGE DIABETES MEDICATIONS, THROUGH 2019
    • TABLE 15: GLOBAL PIPELINE FOR PHASE I STAGE DIABETES MEDICATIONS, THROUGH 2019
    • TABLE 16: GLOBAL PIPELINE FOR DIABETES-RELATED DISORDERS, THROUGH 2019
  • OBESITY AS THERAPEUTIC CATEGORY
    • TABLE 17: GLOBAL PIPELINE FOR OBESITY, THROUGH 2019
    • TABLE 18: DIABETES AND DRUG DEVELOPMENT RESOURCES

CHAPTER 5 - COMPANY PROFILES

  • ACTIVX BIOSCIENCES INC. (KYORIN PHARMACEUTICAL CO. LTD.)
  • AERPIO THERAPEUTICS INC.
  • AMPIO PHARMACEUTICALS INC.
  • AMUNIX
  • ARAIM PHARMACEUTICALS INC.
  • ARISAPH
  • ASTRAZENECA
  • BECTON, DICKINSON AND COMPANY
  • BOEHRINGER INGELHEIM GMBH
  • BRISTOL-MYERS SQUIBB
  • CEBIX INC.
  • CHEMOCENTRYX INC.
  • CODA THERAPEUTICS INC.
  • CONCERT PHARMACEUTICALS
  • CONJUCHEM
  • DIPEXIUM PHARMACEUTICALS INC.
  • DONG-A SOCIO HOLDINGS
  • ELI LILLY AND COMPANY
  • EMISPHERE TECHNOLOGIES INC.
  • EVOKE PHARMA INC.
  • FURIEX PHARMACEUTICALS INC.
  • GENKYOTEX S.A.
  • GLAXOSMITHKLINE PLC
  • GLYCADIA PHARMACEUTICALS
  • HANMI PHARMACEUTICAL CO. LTD.
  • ICO THERAPEUTICS INC.
  • INTARCIA THERAPEUTICS INC.
  • JOHNSON & JOHNSON
  • KOWA CO. LTD.
  • KYORIN PHARMACEUTICAL CO. LTD.
  • KYOWA HAKKO KIRIN CO. LTD.
  • LIGAND PHARMACEUTICALS INC.
  • LG LIFE SCIENCES LTD.
  • MANNKIND CORP.
  • MERCK
  • MERRION PHARMACEUTICALS LTD.
  • MITSUBISHI TANABE PHARMA CORP.
  • NEPHROGENEX INC.
  • NOVARTIS INTERNATIONAL AG
  • NOVO NORDISK A/S
  • ONO PHARMACEUTICALS
  • ORAMED PHARMACEUTICALS
  • OTSUKA PHARMACEUTICAL CO. LTD.
  • PFIZER
  • PHASEBIO PHARMACEUTICALS INC.
  • QUARK PHARMACEUTICALS INC.
  • ROCHE
  • ROYER BIOMEDICAL INC.
  • SANOFI
  • SANWA KAGAKU KENKYUSHO CO. LTD.
  • SATRX LLC
  • SIHUAN PHARMACEUTICAL HOLDINGS GROUP CO. LTD.
  • TAKEDA PHARMACEUTICAL CO. LTD.
  • TRANSITION THERAPEUTICS INC.
  • TRANSTECH PHARMA LLC
  • VIKING THERAPEUTICS INC.
  • ZEALAND PHARMA A/S
  • ZOSANO PHARMA CORP.

LIST OF TABLES

  • SUMMARY TABLE GLOBAL MARKET FOR INCRETIN-BASED THERAPEUTICS, THROUGH 2019 ($ MILLIONS)
    • TABLE 1: DIFFERENCES BETWEEN THE INCRETIN THERAPIES
    • TABLE 2: ADVANTAGES TO ADDING INCRETIN THERAPY
    • TABLE 3: CURRENT THINKING ON DIABETES MEDICATIONS AND CANCER RISK
    • TABLE 4: COMPLICATIONS/COMORBID CONDITIONS FROM DIABETES
    • TABLE 5: COMMERCIALIZED INCRETIN THERAPY
    • TABLE 6: NUMBER OF COMMERCIALIZED INCRETIN-BASED THERAPEUTICS, 2014 AND 2019 (UNITS)
    • TABLE 7: MAJOR AGREEMENTS FOR INCRETIN-BASED THERAPY DEVELOPMENT
    • TABLE 8: GLP-1 RECEPTOR AGONISTS IN LATE-STAGE DEVELOPMENT
    • TABLE 9: GLP-1 RECEPTOR AGONISTS IN EARLY-STAGE DEVELOPMENT
    • TABLE 10: DPP-4 INHIBITORS IN LATE-STAGE DEVELOPMENT
    • TABLE 11: DPP-4 INHIBITORS IN EARLY-STAGE DEVELOPMENT
    • TABLE 12: TOP PHARMA COMPANIES BY REVENUE, 2013 ($ BILLIONS)
    • TABLE 13: BIOLOGICS IN DEVELOPMENT IN THE U.S. BY THERAPEUTIC CATEGORY, 2013
    • TABLE 14: GLOBAL PIPELINE FOR PHASE II AND III STAGE DIABETES MEDICATIONS, THROUGH 2019
    • TABLE 15: GLOBAL PIPELINE FOR PHASE I STAGE DIABETES MEDICATIONS, THROUGH 2019
    • TABLE 16: GLOBAL PIPELINE FOR DIABETES-RELATED DISORDERS, THROUGH 2019
    • TABLE 17: GLOBAL PIPELINE FOR OBESITY, THROUGH 2019
    • TABLE 18: DIABETES AND DRUG DEVELOPMENT RESOURCES

LIST OF FIGURES

  • SUMMARY FIGURE GLOBAL MARKET FOR INCRETIN-BASED THERAPEUTICS, 2012-2019 ($ MILLIONS)
    • FIGURE 1: THE INCRETIN EFFECT ILLUSTRATED
    • FIGURE 2: PERCENTAGE OF DISPENSED PRESCRIPTIONS FOR NON-INSULIN ANTIDIABETICS, 2012 (%)
    • FIGURE 3: PERCENTAGE OF DISPENSED PRESCRIPTIONS FOR GLP-1 RECEPTOR AGONISTS, 2012 (%)
    • FIGURE 4: PERCENTAGE OF DISPENSED PRESCRIPTIONS FOR DPP-4 INHIBITORS, 2012 (%)
    • FIGURE 5: ADA'S STANDARD OF MEDICAL CARE IN DIABETES, 2014
    • FIGURE 6: NUMBER OF COMMERCIALIZED INCRETIN-BASED THERAPEUTICS, 2014 AND 2019 (UNITS)
    • FIGURE 7: MARKET SHARE OF INCRETIN-BASED THERAPEUTICS, BY THERAPEUTIC AREA, 2014 AND 2019 (% OF REVENUE BY THERAPEUTIC AREA)
    • FIGURE 8: MARKET SHARE OF COMMERCIALIZED INCRETIN-BASED THERAPEUTICS, BY INCRETIN TYPE, 2014 AND 2019 (% OF REVENUE BY INCRETIN TYPE)
    • FIGURE 9: MARKET SHARE OF COMMERCIALIZED GLP-1 RECEPTOR AGONISTS, BY DOSING FREQUENCY, 2014 AND 2019 (%)
    • FIGURE 10: NUMBER OF INCRETINS IN DEVELOPMENT BY PHASE, 2014
    • FIGURE 11: GEOGRAPHIC DISTRIBUTION OF PHARMACEUTICAL DRUGS, 2012 AND 2017 (PERCENT OF GLOBAL SALES)
    • FIGURE 12: DIABETES-FOCUSED GEOGRAPHIC TERRITORY: NOVO NORDISK SALES, 2013 (% OF SALES)
Back to Top